Pyrotinib plus capecitabine for HER2+ breast cancer brain metastases
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two oral medications, pyrotinib and capecitabine, for people with HER2-positive breast cancer that has spread to the brain (active brain metastases) and has not responded to newer antibody-drug conjugates like Enhertu. The goal is to see if this drug pair can shrink brain tumors and help control the cancer without needing radiation first.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and in fairly good health (able to be up and about more than half the day).
- Your breast cancer is HER2-positive and has spread to other parts of the body, including at least one brain tumor that can be measured on an MRI.
- You have already tried a drug called Enhertu (T-DXd) or A1811 for active brain metastases, and it stopped working, but you have NOT had radiation to those brain tumors.
- You have not taken capecitabine or pyrotinib before (unless they were given only before surgery and you stayed well for at least 6 months afterward).
- Your heart, kidney, liver, and blood cell counts are within adequate ranges, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether neratinib plus capecitabine can slow or shrink breast cancer that has spread to the brain. It is for people whose cancer shows an “overactive HER2 signal” on a specific tumor test, even though their cancer is labeled HER2-negative.
This trial tests a combination of two oral drugs—capecitabine (a chemotherapy pill) and pyrotinib (a targeted therapy)—for people with HER2-positive breast cancer that has spread. It is for those who have already had a recent type of targeted therapy called an ADC and are looking for a new treatment option that does not require a hospital visit.
This trial tests a combination of targeted drugs (Disitamab Vedotin plus either Pyrotinib or Neratinib) for people with HER2-positive breast cancer that has spread to the brain. The goal is to see if this treatment can help shrink brain tumors or slow their growth.
This Phase 3 trial tests adding pyrotinib to standard hormone-based treatments (fulvestrant or capecitabine) to slow or control metastatic breast cancer. It’s for tumors that are hormone-receptor positive and HER2 positive, where standard options have been used before.
This study tests whether taking pyrotinib (a daily pill) with capecitabine (another pill) after breast cancer surgery can help prevent HER2-positive early-stage breast cancer from coming back. It is for women who have already had their cancer removed and meet certain risk criteria.
This trial tests a combination pill (nilatinib maleate) and chemotherapy (capecitabine) for people with HER2-positive stomach or esophageal cancer that has spread to the brain. The goal is to see if this combo can shrink tumors and control the disease.
Hear when a new Metastatic Breast Cancer in the Brain trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.